Monograph Details
|
|
Infections & Infestations
> Bacterial infections
|
|
CEFOBID |
| Manufacturer |
|
Pfizer Labs |
| Legal Classification |
|
Rx
|
| Pharmacological Class |
|
Cephalosporin. |
| Generic Name |
|
Cefoperazone sodium 1g, 2g; IM or IV inj; sodium content 1.5mEq/g. |
| Indications |
|
Susceptible bacterial septicemia, respiratory or urinary tract, skin and skin structure, gynecologic, intraabdominal infections. |
| Children |
|
Not recommended. |
| Adults |
|
Usually 1–2g IM or IV every 12 hours. Severe: up to 12g/day in 2–4 divided doses. |
| Precautions |
|
Penicillin or other allergy. Hepatic impairment. Hemodialysis patients, see literature. Poor nutritional state, alcoholics, malabsorption states, or recent hyperalimentation monitor prothrombin time. GI disease (esp. colitis). Pregnancy (Cat.B). Nursing mothers. |
| Interactions |
|
Avoid alcohol for at least 72 hours after dosing. Concomitant aminoglycosides may potentiate nephrotoxicity. May cause false (+) Clinitest. Potentiated by probenecid. |
| Adverse Reactions |
|
GI upset, rash, local reactions, anaphylaxis. |
| How Supplied |
|
Vials (1g, 2g)—10 |
| Additional Resources |
|
• Related Prescribing Note |
|
|
|
|
